Skip to content

    Colorectal Cancer Health Center

    Font Size

    Rectal Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Treatment Option Overview


    Median follow-up was 5.7 years. Lethal toxicity was less than 1%, with grade 3 to 4 hematologic toxicity in 55% and 49% of patients in the two bolus arms, respectively (i.e., arms 1 and 3) versus 4% of patients in the continuous-infusion arm. No DFS, OS, or locoregional failure (LRF) difference was detected (across all arms: 3-year DFS, 67% to 69%; 3-year OS, 81% to 83%; LRF, 4.6% to 8%).[17][Level of evidence: 1iiA]

    Addition of radiation therapy

    Although the above data demonstrate a benefit with postoperative radiation therapy and 5-FU chemotherapy for patients with stage II and III rectal cancer, a follow-up study to the NSABP-R-01 trial, the NSABP-R-02 study, addressed whether the addition of radiation therapy to chemotherapy would enhance the survival advantage reported in R-01.[18][Level of evidence: 1iiA] The addition of radiation, while significantly reducing local recurrence at 5 years (8% for chemotherapy and radiation vs. 13% for chemotherapy alone, P = .02), demonstrated no significant benefit in terms of survival. The interpretation of the interaction of radiation therapy with prognostic factors, however, was challenging. Radiation appeared to improve survival among patients younger than 60 years, as well as among patients who received abdominoperineal resection. This trial has initiated discussion in the oncologic community as to the proper role of postoperative radiation therapy. Omission of radiation therapy seems premature, since locoregional recurrence remains a clinically relevant problem.

    Using current surgical techniques, including TME, it may be possible to identify subsets of patients whose chance of pelvic failure is low enough to omit postoperative radiation. A trial conducted by the Dutch Colorectal Cancer Group (DUT-KWF-CKVO-9504) randomly assigned patients with resectable rectal cancers (stages I-IV) to a short course of radiation (5 Gy × 5 days) followed by TME compared with TME alone and demonstrated no difference in OS at 2 years (82% for both arms).[19][Level of evidence: 1iiA] Local recurrence rates were significantly reduced in the radiation therapy plus TME arm (2.4%) as compared with the TME only arm (8.2%, P < .001).

    1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9
    1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9
    Next Article:

    Today on WebMD

    Colorectal cancer cells
    The right diagnosis is the most important factor.
    man with a doctor
    Our health check will steer you in the right direction.
    sauteed cherry tomatoes
    Fight cancer one plate at a time.
    doctor and patient
    Colorectal Cancer Therapy
    Colon vs Rectal Cancer
    New Colorectal Treatments
    can lack of sleep affect your immune system
    Cancer Facts Quiz
    Virtual Colonoscopy
    Picture of the Colon
    Vitamin D